Practical Tips to Interpreting Continuous Glucose Monitoring Metrics

With newer technologies being used to monitor blood glucose levels, how can we use data from continuous glucose monitoring (CGM) to inform the day-to-day management of diabetes?

Our host, Dr. Ronald Goldenberg, takes a deeper look into this topic with Ms. Lori Berard, a Registered Nurse and Certified Diabetes Educator currently working as a Nurse Clinical Research Consultant in Winnipeg. She has authored several chapters in recent Diabetes Canada Clinical Practice Guidelines, notably the 2018 Guidelines on Monitoring Glycemic Control and the 2021 Update for Blood Glucose Monitoring in Adults and Children with Diabetes.

This episode discusses the technical and practical aspects of CGM use and how these newer technologies are changing diabetes care. Our experts touch on the differences between real-time and intermittently scanned CGM, and further explore the clinical relevance of key parameters such as time-in-range (TIR), time-below-range (TBR), and coefficient of variation (CV). They provide practical tips on interpreting ambulatory glucose profiles (AGP) and discuss the benefits and positive impact CGM and metrics beyond HbA1c have had in facilitating shared care in diabetes management.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Goldenberg:

• Direct financial relationship including receipt of honoraria: Abbott, Agora, Amgen, Antibody, AstraZeneca, Bayer, Boehringer Ingelheim, CCRN, CMSKTRG, Eli Lilly, EOCI, HIT Global, HLS, Inceptus, Janssen, LiV, Master Clinician Alliance, MD Briefcase, Merck, Mylan, Novo Nordisk, Sanofi, Script Medical, Servier, STA, Takeda, Toronto Knowledge Translation Working Group, Unik, Valeant. Membership on advisory boards or speaker’s bureau: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS, Janssen, Merck, Novo Nordisk, Sanofi. Funded grants, research or clinical trials: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi.

Ms. Berard:

• Direct financial relationship including receipt of honoraria: Quanta Dialysis Ltd. Membership on advisory boards or speaker’s bureau: Eli Lilly, Sanofi, Novo Nordisk, Abbott, BD, MontMed, Bayer, DEXCOM: Bayer, AstraZeneca, Boehringer Ingelheim, Roche, HLS Therapeutics.